International Journal of Cancer Management
The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences
Nanocarriers Usage for Drug Delivery in Cancer Therapy
Abstract
Acknowledgments
Footnotes
References
- 1.Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-6. [PubMed ID: 18316549]. https://doi.org/10.1158/1078-0432.CCR-07-1441.
- 2.Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750-63. [PubMed ID: 12360278]. https://doi.org/10.1038/nrc903.
- 3.Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207. [PubMed ID: 11384745].
- 4.Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172(12):1487-90. [PubMed ID: 16151040]. https://doi.org/10.1164/rccm.200504-613PP.
- 5.Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull. 2006;29(9):1790-8. [PubMed ID: 16946487].
- 6.Yavari K, Khodabandehloo H, Taghikhani M, Mazidi M, Kalantari B, Asl RS, et al. Development of 166Ho Poly Lactic Acid Microspheres for Radiosynovectomy. J Pharam Pharmacol. 2013;1:25-35.
- 7.Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 2003;92(7):1343-55. [PubMed ID: 12820139]. https://doi.org/10.1002/jps.10397.
- 8.Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-49. [PubMed ID: 11274893].
- 9.Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv. 2010;7(2):145-58. [PubMed ID: 20095939]. https://doi.org/10.1517/17425240903436479.
- 10.Yokoyama M. Clinical Applications of Polymeric Micelle Carrier Systems in Chemotherapy and Image Diagnosis of Solid Tumors. J Expe Clin Med. 2011;3(4):151-8. https://doi.org/10.1016/j.jecm.2011.06.002.
- 11.Svenson S, Tomalia DA. Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106-29. [PubMed ID: 16305813]. https://doi.org/10.1016/j.addr.2005.09.018.
- 12.Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res. 1996;30(1):53-65. [PubMed ID: 8788106]. https://doi.org/10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q.
- 13.Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol. 2002;6(4):466-71. [PubMed ID: 12133722].
- 14.Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers. J Control Release. 2000;65(1-2):133-48. https://doi.org/10.1016/s0168-3659(99)00246-1.
- 15.Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol. 2001;48(1):199-208. [PubMed ID: 11440170].
- 16.Fischer M, Vögtle F. Dendrimers: from design to application—a progress report. Angewandte Chemie Int Edit. 1999;38(7):884-905.
- 17.Sigal GB, Mammen M, Dahmann G, Whitesides GM. Polyacrylamides Bearing Pendant α-Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza Virus: The Strong Inhibition Reflects Enhanced Binding through Cooperative Polyvalent Interactions. J Am Chem Soc. 1996;118(16):3789-800. https://doi.org/10.1021/ja953729u.
- 18.Barth RF, Adams DM, Soloway AH, Alam F, Darby MV. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug Chem. 1994;5(1):58-66. [PubMed ID: 8199235].
- 19.Haensler J, Szoka FJ. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem. 1993;4(5):372-9. [PubMed ID: 8274523].
- 20.Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic Therapy. JNCI J Nation Cancer Inst. 1998;90(12):889-905. https://doi.org/10.1093/jnci/90.12.889.
- 21.Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomed Nanotechnol Biol Med. 2008;4(4):273-82. https://doi.org/10.1016/j.nano.2008.06.002.
- 22.Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40(3):159-70. [PubMed ID: 20359532]. https://doi.org/10.1016/j.ejps.2010.03.019.
- 23.Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49-60. [PubMed ID: 22275822]. https://doi.org/10.2147/IJN.S26766.
- 24.Fan Y, Zhang Q. Development of liposomal formulations: From concept to clinical investigations. Asian J Pharm Sci. 2013;8(2):81-7. https://doi.org/10.1016/j.ajps.2013.07.010.
- 25.Ming-Kung Y. Clinically-Proven Liposome-Based Drug Delivery: Formulation, Characterization and Therapeutic Efficacy. Open Access Scientific Reports; 2012.
- 26.Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491-504. [PubMed ID: 17532091]. https://doi.org/10.1016/j.addr.2007.04.008.
- 27.Kaur T, Slavcev R. Solid lipid nanoparticles: tuneable anti-cancer gene/drug delivery systems. Novel Gene Therapy Approaches. Intech; 2013.
- 28.Xu ZP, Zeng QH, Lu GQ, Yu A. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Engin Sci. 2006;61(3):1027-40.
- 29.Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60(11):1307-15. [PubMed ID: 18555555]. https://doi.org/10.1016/j.addr.2008.03.016.
- 30.Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1(3):325-7. [PubMed ID: 17193451]. https://doi.org/10.1002/smll.200400093.
- 31.Myllynen PK, Loughran MJ, Howard CV, Sormunen R, Walsh AA, Vahakangas KH. Kinetics of gold nanoparticles in the human placenta. Reprod Toxicol. 2008;26(2):130-7. [PubMed ID: 18638543]. https://doi.org/10.1016/j.reprotox.2008.06.008.
- 32.Libutti SK, Paciotti GF, Myer L, Haynes R, Gannon W, Walker M, editors. Results of a completed phase I clinical trial of CYT-6091: A pegylated colloidal gold-TNF nanomedicine. ASCO annual meeting proceedings. 2009. 3586 p.
- 33.McBain SC, Yiu HH, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine. 2008;3(2):169-80. [PubMed ID: 18686777].
- 34.Lubbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996;56(20):4686-93. [PubMed ID: 8840985].
- 35.Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng. 2005;100(1):1-11. [PubMed ID: 16233845]. https://doi.org/10.1263/jbb.100.1.
- 36.Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-83. [PubMed ID: 18582981]. https://doi.org/10.1016/j.jconrel.2008.05.010.
- 37.Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60(8):876-85. [PubMed ID: 18423779]. https://doi.org/10.1016/j.addr.2007.08.044.
- 38.Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57-64. [PubMed ID: 18190833]. https://doi.org/10.1016/j.urolonc.2007.03.015.
- 39.Singh P, Prasuhn D, Yeh RM, Destito G, Rae CS, Osborn K, et al. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release. 2007;120(1-2):41-50. [PubMed ID: 17512998]. https://doi.org/10.1016/j.jconrel.2007.04.003.
- 40.Agirrezabala X, Velazquez-Muriel JA, Gomez-Puertas P, Scheres SH, Carazo JM, Carrascosa JL. Quasi-atomic model of bacteriophage t7 procapsid shell: insights into the structure and evolution of a basic fold. Structure. 2007;15(4):461-72. [PubMed ID: 17437718]. https://doi.org/10.1016/j.str.2007.03.004.
- 41.Sherman MB, Guenther RH, Tama F, Sit TL, Brooks CL, Mikhailov AM, et al. Removal of divalent cations induces structural transitions in red clover necrotic mosaic virus, revealing a potential mechanism for RNA release. J Virol. 2006;80(21):10395-406. [PubMed ID: 16920821]. https://doi.org/10.1128/JVI.01137-06.
- 42.Pokorski JK, Steinmetz NF. The art of engineering viral nanoparticles. Mol Pharm. 2011;8(1):29-43. [PubMed ID: 21047140]. https://doi.org/10.1021/mp100225y.
- 43.Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev. 2006;58(14):1460-70. [PubMed ID: 17113677]. https://doi.org/10.1016/j.addr.2006.09.015.
- 44.Bianco A, Kostarelos K, Partidos CD, Prato M. Biomedical applications of functionalised carbon nanotubes. Chem Commun (Camb). 2005;(5):571-7. [PubMed ID: 15672140]. https://doi.org/10.1039/b410943k.
- 45.Yan J, Xue F, Chen H, Wu X, Zhang H, Chen G, et al. A multi-center study of using carbon nanoparticles to track lymph node metastasis in T1-2 colorectal cancer. Surg Endosc. 2014;28(12):3315-21. [PubMed ID: 24935202]. https://doi.org/10.1007/s00464-014-3608-5.
- 46.Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69(1):1-9. [PubMed ID: 17826969]. https://doi.org/10.1016/j.ejpb.2007.08.001.
- 47.Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol Appl Pharmacol. 2008;229(1):121-34. [PubMed ID: 18355886]. https://doi.org/10.1016/j.taap.2008.02.007.
- 48.Owens D3, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102. [PubMed ID: 16303268]. https://doi.org/10.1016/j.ijpharm.2005.10.010.
- 49.Hoffman AS. The origins and evolution of "controlled" drug delivery systems. J Control Release. 2008;132(3):153-63. [PubMed ID: 18817820]. https://doi.org/10.1016/j.jconrel.2008.08.012.
- 50.Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318. [PubMed ID: 11356986].
- 51.Mohanraj VJ, Chen Y. Nanoparticles-a review. Trop J Pharm Res. 2007;5(1):561-73.
- 52.Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40(7):539-51. [PubMed ID: 11510630]. https://doi.org/10.2165/00003088-200140070-00005.
- 53.Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-57. [PubMed ID: 11001068]. https://doi.org/10.1038/35025220.
- 54.Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633-46. [PubMed ID: 16892078]. https://doi.org/10.1038/sj.onc.1209597.
- 55.Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science. 1980;210(4475):1253-5. [PubMed ID: 7434025].
- 56.Abhilash M. Potential applications of Nanoparticles. Int J Pharm Bio Sci. 2010;1(1):1-12.
Copyright
Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Crossmark
Checking
- Scopus by DOI: 90
Last Update: 1 month ago
- Scopus by Title: 90
Last Update: 1 month ago
- Scopus by Title (Ref): 91
Last Update: 1 month ago
- CrossRef: 35
Last Update: 5 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):
